Oral anticoagulant drug interactions with statins: Case report of fluvastatin and review of the literature

被引:50
作者
Andrus, MR
机构
[1] Univ Alabama, Coll Community Hlth Sci, Tuscaloosa, AL 35487 USA
[2] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA
来源
PHARMACOTHERAPY | 2004年 / 24卷 / 02期
关键词
warfarin; fluvastatin; drug interaction; statin; oral anticoagulant;
D O I
10.1592/phco.24.2.285.33137
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A 67-year-old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio (INR) without bleeding when his atorvastatin therapy was switched to fluvastatin. His warfarin dosage was reduced and his INR stabilized. The fluvastatin was switched back to atorvastatin, and the warfarin dosage was increased to maintain the patient's goal INR. The literature supports a drug interaction between warfarin and fluvastatin due to the strong affinity of fluvastatin for the cytochrome P450 enzyme 2D6. This interaction has not been seen with atorvastatin. Lovastatin also reportedly has caused increases in INR when coadministered with warfarin. It is unclear whether simvastatin interacts with warfarin, but it may increase INRs slightly or increase serum simvastatin levels. One case report describes an interaction between simvastatin and the anticoagulant acenocoumarol, which resulted in an elevated INR. Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione. Thus, until more definitive data are available, clinicians should monitor the INR closely after starting statin therapy in any patient receiving anticoagulation therapy
引用
收藏
页码:285 / 290
页数:6
相关论文
共 21 条
  • [1] LOVASTATIN - WARFARIN INTERACTION
    AHMAD, S
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (11) : 2407 - 2407
  • [2] Beaird S L, 2000, J Am Pharm Assoc (Wash), V40, P637
  • [3] Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors -: The role of metabolism -: Monograph for physicians
    Bottorff, M
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) : 2273 - 2280
  • [4] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [5] SIMVASTATIN DURING WARFARIN THERAPY IN HYPERLIPOPROTEINEMIA
    GAW, A
    WOSORNU, D
    [J]. LANCET, 1992, 340 (8825) : 979 - 980
  • [6] PHARMACOKINETICS OF THE ENANTIOMERS OF ACENOCOUMAROL IN MAN
    GODBILLON, J
    RICHARD, J
    GERARDIN, A
    MEINERTZ, T
    KASPER, W
    JAHNCHEN, E
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (05) : 621 - 629
  • [7] Simvastatin-oral anticoagulant interaction
    Grau, E
    Perella, M
    Pastor, E
    [J]. LANCET, 1996, 347 (8998) : 405 - 406
  • [8] Haines S., 2002, PHARMACOTHERAPY PATH, P337
  • [9] Hoffman H S, 1992, Conn Med, V56, P107
  • [10] Iliadis E A, 1995, Pa Med, V98, P31